Metastatic hormone-sensitive prostate cancer (mHSPC)

Emerging treatment options for metastatic hormone-sensitive prostate cancer (mHSPC); Understanding combination anti-androgen therapy and androgen deprivation therapy

5th October 2022, 16:00 – 17:30 CEST

Prostate cancer is the most common neoplasm in the Western world and remains one of the leading causes of deaths worldwide. Approximately 15% of prostate cancers are diagnosed after the disease has metastasized, and almost 50% of men diagnosed with local prostate cancer will eventually advance to metastatic prostate cancer in their lifetime. All these men will be impacted by metastatic hormone-naïve, or hormone-sensitive prostate cancer (mHSPC), the which precedes the development of metastatic castration-resistant prostate cancer (mCRPC), characterized by poor prognosis and lethality. Therefore, treating mHSPC patients before they advance to mCRPC is of utmost importance. Until very recently, there have been no substantial advancements in the treatment of mHSPC, and survival in this cohort of patients have essentially remained stagnant over the past couple of decades. In recent years, the role of androgen deprivation therapy (ADT) combined with second-generation anti-androgens has been investigated in many phase III clinical trials and has led to new treatment approvals for mHSPC that include abiraterone acetate, apalutamide, and enzalutamide. Given large advances in a small period, a knowledge gap remains as many HCPs remain unaware of these clinical trials as their final analyzed data is more recent, which hinders these HCPs on administering these novel treatments to their patients. Some HCPs are also hesitant on combination therapy using second-generation anti-androgens in mHSPC because of how it will affect downstream treatment options should the patient progress to mCRPC. There are knowledge gaps in the understanding clinical trial evidence for combination second-generation anti-androgen therapy with ADT, as well as understanding how these novel treatments may affect downstream treatment options. The proposed 90-minute interactive, virtual satellite symposium will be hosted at the 9th EUSTM Annual Clinical & Translational Conference (EUSTM-2022). The objective of this event is to increase the knowledge and understanding that HCPs have about the role that second-generation anti-androgen therapies play in treating patients with mHSPC. Effectiveness of the program will be measured through multiple evaluation methods.

Learning Objectives

After completing the independent medical educational activity, learners will be able to:

  1. Understand and explain clinical trial evidence for combination anti-androgen therapy and androgen deprivation therapy (Level 3A & B).
  2. Understand impact of early treatment with combination anti-androgen therapy and androgen deprivation therapy on subsequent therapeutic options (Level 3A & B)
Expert Talk 1: Understanding the Genomic Landscape of Advaced Prostate Cancer

Prof. Che-Kai Tsao
*Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA.

Expert Talk 2: Improving outcomes for patients with non-castrate (castration-sensitive) prostate cancer

Prof. Scott T. Tagawa
*Medical Director, Genitourinary Oncology Research Program, Weill Cornell Medical College, New York, USA

Expert Talk 3: Treatment of Metastatic Castration Sensitive Prostate Cancer

Prof. Neeraj Agarwal
*Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, USA

Expert Panel Discussion and Questions & Answers

Certificate of attendance: The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.

Conflict of interests: No known conflict of interests

Acknowledgment: This symposium is supported by educational grants from Astellas pharma.